Word that a Zytiga phase 3 prostate cancer trial conducted by a unit of Johnson & Johnson...

|By:, SA News Editor
Word that a Zytiga phase 3 prostate cancer trial conducted by a unit of Johnson & Johnson (JNJ) was stopped early positive for efficacy creates a ripple effect with companies involved in developing prostate cancer drugs. Premarket movers: JNJ +0.7%, DNDN -15.1%, MDVN +4.4%.

Subscribe for full text news in your inbox